Is transhumanism really the world’s most dangerous idea?
By Michael Cook,
Mercatornet
| 07. 20. 2016
In 2004 the editors of the journal Foreign Policy asked several prominent intellectuals to identify the world’s most dangerous idea. Surprisingly political scientist Francis Fukuyama’s choice was transhumanism. He described it as a movement “to liberate the human race from its biological constraints”. Its supporters, he said, want to “wrest their biological destiny from evolution's blind process of random variation and adaptation and move to the next stage as a species”.
Most people would ask, “Are you kidding?” In fact, the transhumanist projects which surface in the media do sound improbable, not to say loopy. Here are three which have been widely reported.
- Elon Musk, the American billionaire boss of Tesla and Space X, recently told a conference of programmers in San Francisco that humans need to augment their brain power with “neural lace”, a fine mesh integrated into the brain which would link the brain directly to the internet. If we fail to keep pace with artificial intelligence, we will become house pets for “ultra-intelligent AI”, he said. “I don’t love the idea of being a house cat,” he...
Related Articles
By Jenny Kleeman, The Guardian | 05.30.2026
On a Friday evening in late April, Cathy Tie, the Canadian serial entrepreneur and self-styled “Biotech Barbie”, is centre stage at New York City’s famous Carnegie Hall, performing Saint-Saens’ Piano Concerto No 2 on a gleaming Steinway grand piano, accompanied...
By Virginia Heffernan, The New Republic | 05.29.2026
Here and there, it’s been a good month for humanity—or “magnificas humanitas,” as Pope Leo XIV calls us poor featherless bipeds.
On May 25, the pope published his encyclical letter “on safeguarding the human person in the time of artificial...
By Rebecca Roberts, The Scientist | 05.19.2026
Scientists have had prenatal gene therapy in their sights for decades; by treating the fetus in utero, they can potentially prevent the long-term damage caused by severe, early-onset genetic disorders. Despite its success in preclinical studies, the method has...
By Moe Alsumidaie, The Clinical Trial Vanguard | 05.26.2026
Picture the moment a gene therapy trial’s safety monitor pulls up a patient record — years after the last dose, long after the trial team has dissolved and the CRO contract has closed — and finds a tumor. The vector...